Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Highly Emetogenic Multi-Agent Chemotherapy
NCT07482891Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Mar 2026
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fosrolapitant and palonosetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoint: Percentage of patients achieving Complete Control of CINV. Started Mar 2026; status: recruiting.
02
Drugs
fosrolapitantpalonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07482891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482891.